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Abstract Multiple sclerosis (MS) is a complex neurological
disease where, in genetically predisposed individuals, the
unbalanced interplay between pathogenic and regulatory T
cells will result in the progression of the autoimmune assault
to neural antigens. Fingolimod (FTY720), an oral sphingosine
1-phosphate modulator recently approved for the treatment of
MS, inhibits the egress of T cells from lymph nodes acting
specifically on naïve and memory T cells and sparing effector
T cells. Here we characterized IL-17 and IFNγ producing
effector CD4 and CD8 positive Tcells as well as CD4 positive
CD25highCD127low regulatory T cells in MS patients before
and 1 month after treatment was started. We observed that
fingolimod did not significantly affect the percentage of
CCR6 and CD161 positive T cells in both CD4 and CD8
compartments. In contrast, it significantly reduced the levels
of both CD4+ CCR6+ CD161+ and CD8+ CCR6+ CD161+
producing IFNγ alone or in combination with IL-17. The
percentage of IL-17 secreting cells in both subsets was affect-
ed by the treatment to a lesser extent. Finally, we observed that
CD4+ CD25highCD127low regulatory T cells were decreased
in MS patients compared to healthy controls and fingolimod
significantly increased their frequencies. All together these
findings demonstrate that fingolimod functionally modulates
the ability of potentially pathogenic effector cells to produce
relevant pro-inflammatory cytokines and increases the num-
ber of circulating regulatory T cells possibly contributing in
restoring a balance between these populations.
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Introduction
Multiple sclerosis (MS) is a chronic, inflammatory disease of
the central nervous system (CNS), driven by autoreactive
lymphocytes resulting into an inflammatory cascade and sub-
sequent degeneration of the neural tissue (Compston and
Coles 2008). In healthy condition, the onset of an autoimmune
response against the CNS is prevented by a tightly regulated
balance between self-reacting immune cells and regulatory
lymphocytes including both B and T cells. It is accepted that
both Th1 and Th17 cells contribute toMS development (Lock
et al. 2002; Brucklacher-Waldert et al. 2009; Goverman
2009). Although the implication of Th1 and Th17 CD4+ cells
in the pathogenesis of MS has been largely investigated,
several evidences support also the involvement of CD8+ T
cells (Friese and Fugger 2009). Recently an IL-17-producing
CD8+ T cells subset, named Tc17 has been described (Kondo
et al. 2009) and reported to be present among cells infiltrating
MS tissues (Tzartos et al. 2008; Huber et al. 2013). Moreover,
an expansion of proinflammatory of CD161highCD8+ T cells
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was recently observed in MS subjects (Annibali et al.
2011). In the attempt of maintaining immune homeostasis,
regulatory T cells (Treg) are supposed to control self-
reacting T cells. In humans, CD4+ CD25+ Foxp3+ Tregs
are defined by the low expression of the IL-7 receptor,
CD127, (Liu et al. 2006) and high expression of CD39,
an immunosuppressive ectonucleotidase reported to be
poorly represented on circulating Treg cells of relapsing-
remitting MS patients (Borsellino et al. 2007).
Fingolimod (FTY720), a new sphingosine 1-phosphate
(S1P) receptor modulator, is approved for the treatment of
MS based on results from clinical trials in patients with
relapsing remitting MS (Cohen et al. 2010; Kappos et al.
2010). It causes, in its phosphorylated form, internalization
and degradation of cell membrane-expressed S1P receptor
1, one of the five known S1P receptors, which is critical for
T and B lymphocyte egress from secondary lymphoid or-
gans and thymus. As consequence, lymphocytes retention in
the lymph nodes is favored based on the prevalence of the
signaling through CCR7, a receptor expressed by memory T
cell (Cyster and Schwab 2012). Because of these features,
fingolimod has been shown to significantly decrease the
number of circulating T cells, interfering differently on
naïve and memory T cell subsets (Mehling et al. 2008,
2010). In this study we evaluated the impact of fingolimod
on peripheral blood T cell subsets relevant for MS patho-
genesis with specific focus on the reciprocal relationship
between the effector and regulatory arm of the immune
response occurring in MS patients before and following
FTY720 administration.
Materials and methods
Donors Peripheral venous blood was obtained with in-
formed consent from ten relapsing remitting MS patients
immediately before starting treatment with fingolimod and
1 month after therapy was started. MS patients were treated
with fingolimod 0.5 mg once daily, according to the current
indication for MS treatment. Blood was also obtained from
ten untreated healthy donors matched for age and sex with
MS individuals. The number of patients contributing to each
experiment is indicated in individual figure legends. The
Ethical Committee of the IRCCS San Martino University-
Hospital, Genoa, Italy, approved this study.
Monoclonal antibodies (mAbs) For immunostaining and
analysis by flow cytometry the following mAbs were used:
allophycocianin (APC)-cyanin 7 conjugated anti-CD3,
Horizon 500 conjugated anti-CD3, APC conjugated anti-
CD25, phycoerytrin (PE) conjugated anti-CCR6, PE conju-
gated anti-CD127, Pe-cyanin 7 conjugated anti-IFNγ, fluo-
rescein isothiocynate (FITC) conjugated anti-CD39, Pe-
cyanin 7 conjugated anti-CD4 (Becton Dickinson (BD)
Biosciences); PerCP-cyanin 5.5 conjugated anti-CD8
(Biolegend); FITC conjugated anti-IL-17A (eBioscience);
APC conjugated anti-CD161 (Miltenyi Biotec).
Generation of short-term T cell lines and measurement of
intracellular cytokines Peripheral blood mononuclear cells
(PBMC) were isolated from heparinized venous blood by
using density-gradient centrifugation over Ficoll-Hypaque
(Biochrom). Short term T cell lines were generated by
stimulation of PBMC (3×106 cells) with anti-CD3 and
anti-CD28 mAbs (BD) as described elsewhere (Fenoglio et
al. 2011). Frequencies of cytokines producing cells from
short-term T cell lines were analyzed following stimulation
with phorbo-12-myristate-13-acetate (PMA 50 ng/ml,
Sigma) and ionomycine (2 μg/ml, Sigma) as described
elsewhere (Fenoglio et al. 2011). The cytokine profile of
in vitro expanded T cells was evaluated using a FACSCanto
II flow cytometer (BD Bioscience) by a FACSDiva software
collecting 30000 viable T CD3+ −gated events. Results
were expressed as cytokine positive percentage of CD3+
CD8+ or CD3+ CD8- (for CD4) subsets in activated condi-
tion minus background staining, i.e. percentage of cytokine-
positive T cells of not activated control.
Treg immunophenotyping Treg immunophenotyping was
performed on 1×106/100 μl PBMC incubated with
fluorochrome-conjugated anti-CD3, -CD4, -CD25, -CD127,
-CD39 antibodies. LIVE/DEAD (Invitrogen/Molecular
Probes) was added to exclude dead cells. Samples were ac-
quired and analyzed on FACSCanto II flow cytometer by
FACSDiva software.
Statistical analyses Statistically significant differences be-
tween mean percentage of different T cell subsets observed
in samples from MS patients and controls were analyzed by
Mann–Whitney test for nonparametric values. Calculations
were performed using GraphPad Prism, Version 4.00
software.
Results
Frequencies of CCR6- and CD161-positive cells
are not affected by FTY720
As CD161 and CCR6 are considered reliable markers of
Th17 cells, we analyzed CD161- and CCR6-positive T cells
in the circulating CD4+ and CD8+ T cell pool before and
1 month after the first oral administration of FTY720.
Evaluation was carried out in “ex-vivo” and “TCR-activat-
ed” T cells and compared to circulating T cells from healthy
controls. The “ex vivo” frequencies of CCR6+ and CD161+
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cells both in CD4+ and CD8+ T cells compartments of MS
patients at baseline and after 1 month of therapy did not
significantly differ from those measured in the peripheral
blood from normal donors (Fig. 1a–d). In order to assess
whether activation may lead to a significant change in the
frequencies of these subsets, we performed the same analy-
sis in short-term TCR-activated PBMC derived from MS
individuals at similar time points. Accordingly no signifi-
cant difference was observed in the frequencies of CCR6+
and CD161+ cells in CD4+ and CD8+ subsets regardless of
the time PBMC were isolated before or 1 month after
therapy was started (Fig. 1e–h). Thus, these data suggest
that fingolimod does not significantly affect the peripheral
blood representation of T cells expressing CCR6 and
CD161.
FTY720 significantly reduces CD4+ T cell subsets
producing pro-inflammatory cytokines
Next, we sought to evaluate the content of IFNγ and IL-17 in
these subpopulations following TCR activation. The percentage
of IL-17 producing CD4+Tcells fromMSpatients after 1month
of treatment with fingolimod was significantly decreased com-
pared to the levels observed before treatment (p=0.03; Fig. 2b).
In contrast, a less pronounced effect was observed on IFNγ
producing T cells (Fig. 2a). However, CD4+ T cells producing
both cytokines were significantly diminished after therapy (p=
0.05; Fig. 2c). In the CCR6+ CD4+ subpopulation we observed
a significant effect of treatment on the frequency of IFNγ secret-
ing cells (p=0.01; Fig. 2d) while only a trend was detected for
IL17 (Fig. 2e). However the combined analysis of both cytokines
Fig. 1 Frequencies of CCR6-
and CD161-positive cells in
circulating and TCR-activated
CD4+ and CD8+ T
lymphocytes. Ex vivo
evaluation of CCR6- and
CD161-positive fraction in
CD4 (Panels a–b) and in CD8+
T cells (Panels c–d) derived
from PBMC of ten controls
(HD) and ten MS patients at
baseline (MS t0) and after
FTY720 administration (MS
t1). Percentage analysis of
CCR6+ (Panel e) and CD161+
(Panel f) CD4+ T cells, CCR6+
(Panel g) and CD161+ (Panel
h) CD8+ T cells in short-term
TCR-activated peripheral
lymphocytes derived from ten
MS patients at baseline (t0) and
after FTY720 administration
(t1)
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in CCR6+ CD4+ T cells demonstrated a significant reduction
after 1 month of treatment (p=0.05; Fig. 2f). Similar results were
obtained when the CD161+ CD4+ subset was analyzed,
confirming that FTY720 significantly inhibited the percentage
of IFNγ but not IL17 producing cells compared to before
treatment (p=0.002; Fig. 2g–h). Accordingly, IL-17- and
IFNγ-producing cells were significantly decreased in CD161+
CD4+ Tcells (p=0.02; Fig. 2i). These results suggest that, inMS
patients, treatment with fingolimod leads to a significant decrease
of CCR6+ and CD161+ CD4+ producing both IFNγ and IL-17.
Fingolimod decreases CD8+ T cells producing IFNγ
and IL-17
Next, we sought to address whether administration of
fingolimod could affect the number of IFNγ and IL-17
producing cells within the CD8+ compartment. We
observed a statistically significant drop in the percentage
of IFNγ producing cells (p=0.014; Fig. 3a), whereas the
reduction of T cells producing IL-17 alone or in combina-
tion with IFNγ did not reach statistical significance (Fig. 3b
and c). We detected a significant decrement of CCR6+
CD8+ T cells producing IFNγ alone or in combination with
IL-17 in patients after 1 month of therapy (p=0.003, Fig. 3d
and p=0.009, Fig. 3f respectively). The percentage of IL-17
producing cells in the CCR6+ CD8+ subset did not signif-
icantly differ among MS patients before and after FTY720
treatment (Fig. 3e). Also the number of CD161+ CD8+ T
cells producing IFNγ alone or in combination with -IL17
remarkably dropped after 1 month of therapy compared to
levels detected before fingolimod was started (p=0.05,
Fig. 3g and p=0.03, Fig. 3i respectively). The decrease in
IL-17 producing CD161+ CD8+ T cells was not significant
(Fig. 3h). Because it has been previously reported that
Fig. 2 Cytokine analysis of TCR-activated CD4+ T lymphocytes in
MS patients at baseline (t0) and after FTY720 administration (t1).
Comparison of the frequencies of IFNγ-, IL-17-single and IFNγ and
IL-17-double producing cells in TCR-expanded CD4+ T subset (Panels
a–b–c), in CCR6+ (Panels d–e–f) and in CD161+ (Panels g–h–i) TCR-
expanded CD4+ T cell populations derived from ten MS patients at
baseline (t0) and after FTY720 administration (t1)
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CD161bright T cells co-express CCR6 and are the major
source of IL-17 and IFNγ in the CD8 positive population
(Annibali et al. 2011) we analyzed this subset in MS in-
dividuals before and after fingolimod therapy. The frequen-
cies of CD8+ CD161highCCR6+ T cells producing IFNγ
alone or in combination with IL-17 was significantly re-
duced in patients treated with fingolimod compared to levels
detectable before starting the therapy (p=0.005; Fig. 3j and
p=0.03 Fig. 3l).
These findings prove that, similarly to what observed for
CD4+ T cells, also levels of circulating CD8+ T cells ex-
pressing CD161 and CCR6 and producing IFNγ and, to a
lesser extent, IL-17 are decreased 1 month after fingolimod
was started.
Treg are increased in MS patients treated with FTY720
Next we analyzed the possibility that fingolimod may have an
impact on CD4+ Tregs as defined by the expression of CD25
and CD127 on T cells in the peripheral blood of MS patients
before and after therapywas started. Furthermore, the percentage
of Tregs in healthy controls was also compared to MS individ-
uals at both time points. The comparison between controls and
MSpatients at baseline showed a statistically significant decrease
of this subset in the peripheral blood of untreatedMS subjects (p
=0.005; Fig. 4a). Noteworthy, we detected a statistically signif-
icant increment (p=0.014; Fig. 4a) of circulating Treg cells in
MS patients after fingolimod treatment, back to levels similar to
those observed in healthy controls. We observed also a remark-
able reduction of expression levels of CD39 on CD4+
CD25highCD127low T cells in MS patients at baseline compared
to controls (p=0.006; Fig. 4b). CD39 expression was increased
on Tregs 1 month after fingolimod was started (Fig. 4b).
Frequencies of CD39 expressing CD8+ were not changed in
MS patients between the two time points (data not shown).
These findings confirm that Treg levels are decreased in MS
subjects and suggest that fingolimod can restore their levels
similar to those detected in healthy controls.
Discussion
Multiple sclerosis is an autoimmune disease where T cells
probably recognizing myelin antigens are playing a major role
(Goverman 2009). Autoimmune diseases may develop from
an unbalanced relationship between effector and regulatory
arms of the immune system (Wing and Sakaguchi 2010;
Fenoglio et al. 2011). Current evidence acquired from both
Fig. 3 Cytokine analysis of TCR-activated CD8+ T lymphocytes in
MS patients at baseline (t0) and after FTY720 administration (t1).
Comparison of the frequencies of IFNγ-, IL-17-single and IFNγ and
IL-17-double producing cells in TCR-activated CD8+ T subset (Panels
a–b–c), in CCR6+ (Panels d–e–f), CD161+ (Panels g–h–i) and
CD161bright (Panels j–k–l) of short-term TCR-activated CD8+ T cell
populations derived from ten MS patients at baseline (t0) and after
FTY720 administration (t1)
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animal models andMS individuals suggests the involvement of
CD4 positive T helper cells producing IFNγ and IL-17, char-
acteristics of a Th1 and Th17 phenotype (Lock et al. 2002;
Brucklacher-Waldert et al. 2009). However, T helper subsets
are highly heterogeneous as demonstrated by the ability of T
cells to often coproduce IL-17 and IFNγ (Kebir et al. 2009;
Cosmi et al. 2011). A higher level of complexity is provided by
the involvement of CD8 positive T cells in MS pathogenesis
(Friese and Fugger 2009). A better elucidation of such intricate
picture has been favored by the recent identification of markers,
such as the NK receptor CD161, specifically associated with
Th17 profile (Cosmi et al. 2008). Th17 cells may acquire a non-
classical Th1 phenotype upon inflammatory cues as depicted
by the expression of the Th17 marker CD161 (Cosmi et al.
2008). In addition, recent reports suggest a role in MS patho-
genesis for IL-17–producing CD8+ T cells (Tc17) (Tzartos et
al. 2008; Huber et al. 2013), based on the observation that
CD8+ T cells detected in the CNS and cerebrospinal fluid of
MS individuals produce IL-17. A pathogenic role for CD8+ T
cells is further supported by the observation that
CD161highCD8+ T cells are expanded in the peripheral blood
and display proinflammatory features including the ability to
produce IL-17 (Annibali et al. 2011). Th17 cells also express
high levels of CCR6, a receptor involved in the entry of
pathogenic T cells into the CNS (Reboldi et al. 2009). In this
study we analysed the impact of fingolimod, a new oral drug
approved for the treatment of relapsing remitting MS, on clas-
sical and non-classical Th17 subsets relevant for MS pathogen-
esis. FTY720 has been previously demonstrated to significantly
decrease the number of circulating CD4+ and, to a lesser extent,
CD8+ T cells, affecting mainly naïve and central memory T
cells, while sparing CCR7- effector memory T cells, possibly
involved in the efficient control of microbial infections ob-
served in treated patients (Mehling et al. 2008). FTY720 sig-
nificantly decreased peripheral blood levels of IL-17 producing
T cells, which were demonstrated to reside mainly in the
CCR4+ CCR6+ CD4+, thus supporting their, drug induced,
retention in the secondary lymphoid organs (Mehling et al.
2010). In contrast with the latter study we demonstrated that
fingolimod modestly affects the ex-vivo relative frequencies of
CCR6+ CD161+ T cells both in the circulating CD4 and CD8
positive compartments of MS patients when compared to levels
observed before therapy was started. Similar results were ob-
served when these subsets were evaluated following short term
in vitro stimulation suggesting that T cell activation, in
fingolimod-treated patients, does not result in a significant
change of these subpopulations. However, in agreement with
Mehling and collaborators (Mehling et al. 2010), we observed
that fingolimod administration resulted in a significant change
of the frequencies of CD4 positive T cells producing IL-17
alone or in combination with IFNγ. In the CD8 positive Tcells,
FTY720 affected mainly the IFNγ-producing subset.
Accordingly, when the phenotype of potentially pathogenic T
cells was further dissected, we observed that treatment
decreased frequencies of CCR6+ and CD161+ T cells
producing IL-17 in combination with IFNγ or IFNγ alone
both in the CD4+ and in the CD8+ compartments. In
particular, fingolimod significantly reduced levels of CD8+
CD161highCCR6+ T cells producing IFNγ alone or in
combination with IL-17, a subset of CD8 positive T cells
endowed by a remarkable pathogenic potential in MS
(Annibali et al. 2011). These results further confirm that
fingolimod appears to affect significantly CD4+ Th17 cells
but also IFNγ producing Th17 cells, a non-classical
Th1/Th17 subpopulation, which is dynamically generated
from classical Th17 cells under inflammatory condition
(Annunziato et al. 2012). The preferred effect of fingolimod
on CCR6+ CD161+ IFNγ and IL-17 co-producing T cells
might be explained by the inability of Th17 cells to pro-
liferate upon TCR stimulation under inflammatory condi-
tions because of reduced responsiveness to IL2 and
impairment of RORC-dependent pathways that lead to IL2
Fig. 4 Analysis of Treg frequencies in the peripheral blood of MS and
healthy individuals. Comparison of the frequency of CD4+
CD25highCD127- (Panel a) and CD39+ CD25highCD127low CD4+
circulating Treg cells from ten healthy donors and ten MS patients at
baseline and after FTY720 therapy
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production and cell proliferation resulting in a limited Th17
cells expansion at sites of inflammation (Santarlasci et al.
2012). In addition, these findings further support a selective
effect of fingolimod on different T cell populations in MS in-
dividuals (Mehling et al. 2008, 2010), probably based on its
ability to modulate S1PR1 on lymphocytes and therefore con-
trolling their egress from lymphoid organs (Cyster and Schwab
2012). Of note, we observed also a statistically significant re-
duction of the frequencies of CD4+ CD25highCD127low T cells
in MS subjects naïve of therapy compared to controls. An
impairment of Treg functions has been described inMS patients,
which may underlie the compromised control of auto-reactive
cells (Viglietta et al. 2004). Interestingly, the frequency of CD4+
CD25highCD127low T cells was significantly increased close to
levels observed in controls 1 month after fingolimod was started.
These results are in line with the recent report that CD127
polymorphisms can influence the frequency of circulating Treg
in MS patients (Broux et al. 2010). Accordingly, we detected a
drastic decrease in the percentage of CD39 expressing CD4+
CD25highCD127low Tregs in MS patients compared to controls,
which was significantly increased after FTY720 was started.
These results are of remarkable importance as it has been
suggested that CD39, an ectoenzyme with immunosuppressive
features due to its involvement in ATP degradation, plays a
major role in Treg activity leading to defective Tregs functions
in CD4+ (Borsellino et al. 2007) and CD8+ subsets (Parodi et al.
2013). Therefore fingolimod increases the circulating levels of
CD39-expressing Tregs consistent with the capability to restore
Treg homeostasis and functions in MS patients. Taken together
these data suggest a double beneficial role of fingolimod in
negatively modulating inflammatory T cell circulation and/or
activation and restoring Treg homeostasis. Based on this scenar-
io, the analysis of frequencies of peripheral effector and regula-
tory T cell populations and their mutual balance, is of particular
interest for the assessment of the mechanisms of action of
immunomodulatory drugs relevant to MS treatment.
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